Senate Bill 38 directs the Oregon State Board of Pharmacy to study prescription drugs and prepare a report for the Legislative Assembly’s interim health care committees. The report may include recommendations for legislation and must be submitted by September 15, 2026, in the form required by Oregon public records/reporting law.
The measure is a study bill rather than a direct regulatory change. It does not itself alter prescription drug pricing, access, dispensing rules, or pharmacy licensing standards, but it creates a formal legislative review process that could lead to future policy proposals based on the board’s findings.
Impact
SB 38 would temporarily assign the State Board of Pharmacy a research and reporting duty on prescription drugs, with the study authority expiring on January 2, 2027. Its immediate legal effect is limited to requiring a report to the legislature; it does not amend existing pharmacy statutes or impose new substantive requirements on pharmacies, prescribers, insurers, or patients. Any broader impact would depend on whether the board’s recommendations lead to later legislation.
Sentiment
Because there are no committee transcripts or recorded votes provided, the available record shows no documented debate or opposition. The bill’s structure as a study measure suggests a generally neutral or exploratory posture, aimed at gathering information for future health care policymaking rather than advancing an immediate policy shift.
Contention
No specific points of contention are documented in the provided materials. Potential areas of interest, if discussed later, would likely include the scope of the study, whether the board has sufficient resources or expertise to evaluate prescription drug issues, and what policy topics the report should cover, such as drug costs, access, shortages, or pharmacy regulation.